** Shares of drug developer Leap Therapeutics LPTX.O fall 67.1% to 74 cents premarket
** Co says it will not move forward with late-stage trials of its drug, sirexatamab, in patients with gastric cancer
** Says drug will show negative results for ongoing mid-stage trial's main goal of progression free survival when study completes
** Will explore partnership opportunities to test sirexatamab in combination with a type of cancer drugs called anti-PD-1 antibodies for treatment of gastric cancer and other diseases
** Up to last close, stock down 7.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.